Latest JC virus Stories
ATLANTA, Aug. 16, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001.
This report provides perspective on the MS landscape in light of Merck Seronoâ€™s decision to discontinue development and marketing of cladribine for MS. Scottsdale, AZ (PRWEB) June 27, 2011 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled â€œThought Leader Insight & Analysis: Multiple Sclerosis,â€ designed to provide critical strategic insight for pharma and biotech companies...
Collaboration may lead to advances in detection of, treatment of, and even vaccination against colorectal and other cancers DALLAS and HOUSTON, Feb.
AMSTERDAM, and RESEARCH TRIANGLE PARK, N.C., Nov.
The JC polyomavirus doesn't strike very often, but when it does, this mean bug can leave a devastating path.
The JC polyomavirus doesn't strike very often, but it's a mean bug that preys on people with weakened immune systems, including people with AIDS, and almost always kills them.
The Merkel cell polyomavirus (MCPyV) is the only human polyomavirus known to be associated with a rare skin cancer, known as Merkel cell carcinoma, according to a new study published online September 23 in the Journal of the National Cancer Institute.
The source of PML, the JC virus, is found to be reactivated in multiple sclerosis patients receiving natalizumab treatment.
The U.S. Food and Drug Administration says Genentech Inc.